



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A61K 38/20, 39/12, 39/39, 48/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/29091 (43) International Publication Date: 26 September 1996 (26.09.96)</p>
<p>(21) International Application Number: PCT/GB96/00686 (22) International Filing Date: 22 March 1996 (22.03.96) (30) Priority Data: 9505784.0 22 March 1995 (22.03.95) GB (71) Applicant (for all designated States except US): CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED [GB/GB]; The Old Schools, Cambridge CB2 1TS (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): STANLEY, Margaret, Anne [GB/GB]; 48 Glisson Road, Cambridge CB1 2HF (GB). SCARPINI, Cinzia, Giuseppina [IT/GB]; 14 West Street, Comberton, Cambridge CB3 7DS (GB). (74) Agents: WALTON, Sean, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: TREATMENT OF PAPILLOMAVIRUS-ASSOCIATED LESIONS USING INTERLEUKIN-12 (57) Abstract <p>Interleukin-12 (IL-12) or a functional analogue thereof, or a polynucleotide encoding IL-12 or encoding a functional analogue thereof, is used as a therapeutic material or adjuvant in treating papillomavirus-associated lesions e.g. warts due to HPV 6 and/or 11, e.g. condyloma acuminata. IL-12 or a vector encoding it for endogenous production can be used together with a vaccine such as a papillomavirus antigen, or a vector encoding a papillomavirus antigen.</p></p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TREATMENT OF PAPILLOMAVIRUS-ASSOCIATED
LESIONS USING INTERLEUKIN-12

FIELD OF THE INVENTION

5 This invention relates to materials and methods for treatment of papillomavirus-associated lesions, e.g. HPV-associated lesions such as the tumours designated as genital warts. The invention also relates to methods of producing and using such materials, including immuno-therapeutic materials such as vaccines and adjuvants.

BACKGROUND OF THE INVENTION AND PRIOR ART

10 Many proliferative conditions are known to be associated with papillomaviruses, in particular varieties of warts, such as condyloma acuminata (anogenital warts) and cervical intraepithelial dysplasia and neoplasia, which can develop into cervical cancer.

15 Condyloma acuminata is caused by infection with human papillomavirus, usually HPV types 6 and 11, and is the most commonly diagnosed viral sexually transmitted disease in the UK. Significant morbidity is associated with the lesions, and available treatment regimes are unsatisfactory, with many patients exhibiting recurrent disease. Other HPV types, particularly 16 and 18, are associated with development
20 of intraepithelial dysplasia and neoplasia which may progress to invasive carcinoma tumours of the cervix and (more rarely) of the vulva, vagina or penis. Furthermore, one study showed cervical intraepithelial neoplasia in 50% of patients with visible genital warts (PG Walker et al, (1983) Br J Ven Dis 59:120-123).

25 A proportion (about 20%) of patients with condylomata undergo spontaneous regression of their tumours, apparently reflecting an effective immune response mounted by the host. S Aiba et al ((1986) Cancer 58: 1246-1251) reported that tumour regression was characterised by an active cell-mediated immune response in which CD4+ T lymphocytes and macrophages predominate, consistent with a delayed type hypersensitivity
30 response to foreign antigen.

Vaccines have previously been proposed for prophylaxis and therapy of papillomavirus-associated conditions. Thus for example WO 93/00436 (Cancer Research Campaign Technology: WFH Jarrett et al) concerns the use
35 of papillomavirus protein L2, and of related fragments and fusion proteins, for prophylaxis and therapy of papillomavirus-associated conditions; WO 93/20844 (Cancer Research Campaign Technology: MS Campo et al) relates to vaccine uses of papillomavirus E7 protein; and WO 93/02184 (University of Queensland and CLS Ltd: I Frazer et al: Papilloma

Virus Vaccine) relates to papillomavirus-like particles comprising L1 protein or L1 and L2 protein and their use as vaccine.

Furthermore WO 96/00583 (Merck: JJ Donnelly et al: Polynucleotide Vaccine for Papillomavirus) describes DNA constructs encoding papilloma virus gene products, capable of being expressed upon direct introduction
5 into animal tissues, as prophylactic pharmaceuticals which can provide immune protection against infection by papilloma virus.

In the field of immunology large numbers of cytokines and accessory substances are known, of which one of the known cytokines is now
10 designated IL-12. WO 92/05256 (Genetics Institute and Wistar Institute: G Trinchieri et al: Natural Killer Stimulatory Factor) describes IL-12 as a human cytokine under the designation natural killer stimulatory factor. WO 92/05256 contains a recommendation, in general terms, to use NKSF or one or both of its subunits or peptide fragments thereof in a suitable
15 pharmaceutical carrier, in "methods for treating cancer, viral infections such as AIDS, bacterial infections and other disease states responsive to the enhanced presence of gamma interferon or GM-CSF production".

EP 0 433 827 (Hoffmann-la Roche: RA Chizzonite et al: Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto)
20 describes IL12 under the designation cytotoxic lymphocyte maturation factor (CLMF). IL-12 has been alternatively designated as natural killer cell stimulatory factor.

Reference in connection with IL-12 is also made to M Kobayashi et al, J Exp Med (Sep 1989) 170(3) 827-845 "Identification and purification
25 of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes"; to A S Stern et al, Proc Nat Acad Sci USA (Sep 1990) 87:6808-6812, "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells"; and to S F Wolf et al, J Immunol (May 1991)
30 146(9):3074-3081, "Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells". IL-12 occurs as a heterodimer of two covalently linked polypeptide chains, p40 and p35, the products of distinct genes. IL-12 has been reported as produced by monocytes/ macrophages, B cells,
35 mast cells and by NK cells. An IL-12 receptor has been found on activated T cells and activated NK cells, and is a single transmembrane glycoprotein of 70-75 kDa. IL-12 has been reported to promote the growth of activated NK, CD4+ and CD8+ T cell subsets and to increase both antibody dependent cellular cytotoxicity and NK mediated cytotoxicity. IL-12 is also an

inducer of interferon-gamma (IFN-gamma) which can activate macrophages.

A report of injecting interferon-gamma (one of the cytokines) into genital warts has been made (LJ Eron et al. (1986) New Engl J Med. vol 315(17); and L Belli et al (Condylomata International Study Group),
5 (1991), J Amer Med Ass. vol 265(20) (May 22/29).).

The prior art leaves it still desirable to seek further treatments for papillomavirus-associated conditions and for the tumours to which these can give rise.

10 SUMMARY AND DESCRIPTION OF THE INVENTION

The present invention arises from a surprising finding that IL-12 is present in 100% of regressing HPV-induced tumours surveyed by the present inventors in a clinical study - unlike many other cytokines also surveyed.

15 Given the association between the presence of IL-12 in lesions resulting from HPV infection and regression of these lesions, the present invention therefore provides various aspects concerned generally with therapy of papillomavirus-associated lesions, e.g. treatment of tumours. The conditions to which the invention is applicable include any
20 papillomavirus infection, and in particular include any epithelial cell proliferation induced as a consequence of infection with a human or non-human animal papillomavirus including benign warts or cutaneous or mucosal surfaces including skin, cervix, vagina, vulval, anus, rectum, penis, meatus, urethra, larynx, oropharynx, buccal cavity, tongue, and
25 nasopharynx. The invention is also applicable to malignant lesions associated with papillomavirus infection such as anogenital cancers including cervix, vulva, anus, penis; and cutaneous, laryngeal and oesophageal cancers. Of particular interest is the treatment of anogenital warts such as those caused by HPV types 6 and 11.

30 According to the present invention, therefore, the cytokine interleukin-12, (IL-12) and functional analogues thereof, are provided for use as therapeutic materials or as adjuvants in the treatment of papillomavirus-associated lesions.

35 Such lesions can be for example warts caused by HPV type 6 and/or type 11, such as genital warts, also known as anogenital warts, or condyloma acuminata.

Also provided by the present invention as therapeutic materials or as adjuvants in the treatment of papillomavirus-associated lesions, are polynucleotides encoding IL-12 or encoding functional analogues thereof.

Aim of treatments according to embodiments of the invention is to increase the amount of IL-12 in an individual, especially for example at a tissue location where immune response to papillomavirus can have therapeutic effect, e.g. at or in the neighbourhood of a lesion associated with HPV.

According to the invention, IL-12 itself can be administered to an individual with an HPV-associated lesion for treatment of the lesion.

Alternatively, according to certain examples of the invention, an inducer of IL-12 (e.g. in the form of a polynucleotide, e.g. carried by a recombinant virus vector encoding IL-12 and able to cause expression of the encoded IL-12 when it infects a cell) can be administered to an individual with an HPV-associated lesion for treatment of the lesion. Generally such an inducer can be a material, e.g. a molecular species, able to induce a local or systemic increase in the level of IL-12, e.g. as a result of increased endogenous production or release of IL-12 by cells.

Thus, according to the invention, pharmaceutical compositions for use in the treatment of papillomavirus-associated conditions such as tumours can comprise IL-12 or an inducer thereof; and IL-12 and inducers thereof can be used in methods for the manufacture of medicaments, compositions for use in therapy of papillomavirus-associated conditions, e.g. in anti-tumour treatment.

The IL-12 or inducers thereof can be present in admixture together with further component(s) as described below.

Thus the invention provides in one aspect a pharmaceutical treatment material comprising IL-12, or a functional analogue thereof, for use as an immunotherapeutic or as a vaccine adjuvant; e.g. for use in treatment of papillomavirus-associated tumours.

The pharmaceutical treatment material can comprise in combination (i) IL-12, or a functional analogue thereof, for use as a vaccine adjuvant, and (ii) a papillomavirus antigen, or a vector encoding and able to cause expression of a papillomavirus antigen, for use as a vaccine.

Component (ii) can comprise at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto; e.g. a polypeptide with at least a substantial part of the sequence of at least one of proteins E1, E2, E4, E5, E6, E7, L1, and/or L2 of HPV 6, 11, 16 and/or 18. Generally in the invention the corresponding proteins and antigens of HPV types 31, 31, 35, 45, 51, 52 and 56 are also applicable, particularly for example in connection with papillomavirus lesions

associated with cervical intraepithelial neoplasia or the risk thereof.

Alternatively component (ii) can comprise a recombinant virus vector encoding and able to cause expression of at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto. Such a vector can comprise at least one recombinant vaccinia virus encoding a polypeptide with at least a substantial part of the sequence of at least one papillomavirus protein E1, E2, E4, E5, E6, E7, L1, and/or L2 of HPV 6, 11, 16 and/or 18.

Alternatively, as stated above, inducers of IL-12 can be used. The present invention can in certain embodiments include the use of polynucleotides encoding one or both subunits (chains) of IL-12 such as the p40 subunit together with the p35 subunit of IL-12, or in certain cases encoding the p40 subunit alone, and other functional analogues thereof, as therapeutic materials or as an adjuvant in the treatment of papillomavirus-associated lesions.

This can be useful for example in connection with tissues such as keratinocytes which are capable of constitutively expressing the p35 chain but not the p40 chain of the heterodimer IL-12 (G Muller et al, 1994, J Clin Invest 94:1799-1805). IL-12 activity has been reported to depend in normal conditions in vivo on a heterodimeric form involving a p40 subunit (ML Kobayashi et al 1989 J Exp Med 170:827-832; SF Wolf et al, 1991, J Immunol 146:3074-3081).

Thus, for example, in further aspects the invention provides pharmaceutical treatment material comprising a polynucleotide encoding and able to cause expression of IL-12, or its p40 subunit, or other functional analogue thereof, for use as an immunotherapeutic or as a vaccine adjuvant.

The polynucleotide can form part of a recombinant virus vector, e.g. a genetically disabled herpesvirus vector (for which reference is made to WO 92/05263 and WO 94/21807 (Immunology Ltd/Cantab Pharmaceuticals: Inglis et al), and WO 92/16636 (Immunology Ltd: Boursnell et al)). In this connection, the virus vector can for example comprise a mutant HSV1 or HSV2 having a deletion in the gH gene, and carrying (at the locus of deletion of gH) an inserted heterologous gene or genes encoding IL-12, or its p40 subunit, or other functional analogue thereof. Alternatively, plasmid DNA or a more complex vector can be used, e.g. with suitable regulatory sequences for expression in eukaryotic cells.

Such a polynucleotide encoding and able to cause expression of IL-12, or a functional analogue thereof, can be used as a vaccine

adjuvant, in combination with a papillomavirus antigen, or a vector encoding and able to cause expression of a papillomavirus antigen, for use as a vaccine. Examples of such vaccine elements can be as already stated above.

5 If desired, the polynucleotide encoding the IL-12 or analogue can be encoded and carried by the same vector that encodes the papillomavirus antigen, and can be encoded either as separate proteins or as a fusion protein e.g. containing HPV-derived aminoacid sequence, and aminoacid sequence from one or other or both of the IL-12 chains.

10 Endogenous production of IL-12 can also be induced in a treated subject by a local or distally administered stimulus such as an adjuvant, along with any other desired treatment e.g. a vaccine.

 Treatment methods according to the invention include treatments to increase the level of IL-12 in or around a papillomavirus-associated
15 lesion such as a tumour by administration of a pharmaceutical according to the invention in the vicinity of the lesion, e.g. in the case of an external or accessible tumour of skin or mucosa.

 IL-12 protein can be sole active ingredient in a pharmaceutical composition according to the invention: e.g. as biologically active
20 heterodimeric IL-12 protein administered per se locally at or near a lesion site or systemically: local administration is preferred. Alternatively, further active ingredients such as vaccines can be given. Vaccines that can be used alongside the IL-12 or inducer thereof include killed HPV preparations, or killed or live vectors such as vaccinia virus
25 vector, carrying nucleic acid encoding HPV protein(s) or antigen(s); or corresponding 'naked DNA'. Suitable HPV proteins to encode include those mentioned elsewhere herein.

 Pharmaceutical compositions according to examples of the present invention can be formulated to be given e.g. orally, or by injection,
30 which can be cutaneous, subcutaneous, intravenous, intramuscular or intradermal.

 Pharmaceutical compositions according to examples of the present invention can comprise, in addition to the respective active ingredient, pharmaceutically acceptable vehicles, excipients, carriers, other
35 adjuvants, buffers, stabilisers and other per-se known materials, preferably non-toxic and free from incompatibility with the chosen active ingredients. Those pharmaceutical compositions which are for topical administration can comprise creams and emulsions. Where proteins are given they can be given e.g. in aqueous buffer or in known slow release

form such as liposomes and microparticles. Oral compositions can be given as tablets or capsules e.g. comprising gelatin, or as powders or liquids. Liquid compositions can comprise water, e.g. as physiological saline or dextrose or other saccharide solution, glycerin or other glycols, ethylene
5 or propylene glucols or polyethylene glycol; petroleum; animal, vegetable, mineral or synthetic oils.

Pharmaceutical compositions for injection can comprise per-se known sterile injectable vehicles, often pyrogen-free, with suitable pH, isotonicity and stability, e.g. isotonic vehicles such as sodium chloride
10 injection, Ringer's injection, and lactated Ringer's injection. Suitable examples of vehicles for giving IL-12 by injection can comprise buffer, human serum albumin and glycine, or human serum albumin and saline for injection (see LJ Eron et al, (1986) New Engl J Med, vol 315(17); and L Belli et al (Condylomata International Study Group), (1991), J Amer Med
15 Ass, vol 265(20) (May 22/29)).

Therapeutically effective amounts of the materials provided for use according to the present invention can be as mentioned below or can be as readily determined by quantitative assessment of tumours e.g. as tumour area or volume.

20 Alternatively, dosage and progress of treatment can be assessed by biopsy of the lesions and assessment of the levels or the expression of IL-12 present therein, by immunoassay or other immunochemical determination (as can be readily adapted from per-se wellknown immunoassay or immunochemical methods by using antibody of appropriate binding
25 specificity for IL-12); or by PCR methods, for example as described below.

Dosages of active ingredient can thus be as mentioned herein or as otherwise adjusted by a prescribing physician according to the location, type and severity of lesions in a clinical case under treatment and the
30 indications provided by such assay methods.

Protein IL-12 can be injected as sole active ingredient in the range 1pg to 1mg per dose, e.g. in the range 10pg to 10micro-g per dose, e.g. in the range 10pg to 1 micro-g per dose. When used as a vaccine adjuvant the dose can for example be in the range 1pg to 10 micro-g per
35 dose, e.g. 100pg to 1 micro-g per dose.

In the use of DNA encoding IL-12, the dose can be for example 1ng to 1mg per dose, e.g. 100ng to 100 micro-g per dose.

The treatments described herein can be combined with other forms of treatment, e.g. administration of anti-tumour compositions and/or other

cytolytic or cytodestructive treatment, including surgical excision, cryosurgery, electrocauterisation, laser therapy and application of podophyllum resin. The different treatments can be simultaneous or sequential.

5 The invention is further described for illustration and not by way of limitation by reference to the following examples and associated test methods:

USE OF IL-12 AS AN IMMUNOTHERAPEUTIC FOR HPV TUMOURS:

10 For this use, recombinant IL-12 can be produced in-vitro by expression of both the p35 and p40 chains of IL-12 in a suitable expression system, preferably a mammalian cell expression system but alternatively in a yeast or baculovirus expression system. Such expression systems are well known in the art of rDNA technology and known
15 cloning and expression vectors and other relevant materials can be readily adapted to the expression of IL-12. WO 92/05256 (Genetics Institute and Wistar Institute: G Trinchieri et al: Natural Killer Stimulatory Factor) describes IL-12 as a human cytokine under the designation natural killer stimulatory factor, and describes methods for producing it and
20 pharmaceutical preparations containing it. EP 0 433 827 (Hoffmann-la Roche: RA Chizzonite et al: Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto) describes IL12 under the designation cytotoxic lymphocyte maturation factor (CLMF) and describes its production and synthesis by a human B-lymphoblastoid cell line.

25 IL-12 so produced can be purified by per-se standard techniques, e.g. as described in WO 92/05256 (Genetics Institute and Wistar Institute: G Trinchieri et al) and EP 0 433 827 (Hoffmann-la Roche: RA Chizzonite et al) and other references noted above.

30 Recombinant IL-12 preparations can be used to treat genital warts, and can be formulated with pharmaceutically acceptable carriers, for example as aqueous solutions, or as encapsulated forms e.g. in biodegradable microparticles or liposomes, or in aqueous cream formulations of the protein.

35 Applied topically, e.g. directly to the HPV wart or other lesion, IL-12 can be applied for example in a dose range of 0.01-1000 microgram/day.

Pharmaceutical formulations of IL-12 for this purpose can be topical preparations or parenteral, especially injectable, preparations.

USE OF IL-12 AS AN ADJUVANT TO AN HPV VACCINE:

IL-12 can also be used to treat HPV disease by use as a vaccine adjuvant.

5 HPV vaccines to which IL-12 can be added as an adjuvant include recombinant HPV proteins, fusion proteins, fragments, or peptides: for example those described in WO 93/00436 (Cancer Research Campaign Technology: WFH Jarrett et al) which concerns the use of papillomavirus protein L2, and of related fragments and fusion proteins, for prophylaxis and therapy of papillomavirus-associated conditions.

10 Such vaccines can be combined with another adjuvant such as aluminium hydroxide gel e.g. in the form of a preparation known as Alhydrogel (TM), and with per-se known biodegradable microparticles or liposomes.

15 Alternative forms of HPV vaccines with which IL-12 can be combined include recombinant virus-like particles, e.g. as described in WO 93/02184 (University of Queensland and CLS Ltd: I Frazer et al: Papilloma Virus Vaccine).

20 Alternatively nucleic acid based plasmid vaccines, e.g. as described in WO 96/00583 (Merck: JJ Donnelly et al: Polynucleotide Vaccine for Papillomavirus) can be used in conjunction with IL-12 or polynucleotide encoding it.

25 Alternatively, recombinant vectors such as vaccinia virus vectors, e.g. those carrying genes encoding HPV proteins or related fusion proteins, e.g. as described in WO 92/16636, can be used. WO 92/16636 (Immunology Ltd: MEG Boursnell et al: Recombinant Virus Vectors Encoding Human Papillomavirus Proteins) describes for example recombinant virus vectors encoding part or all of HPV wild-type proteins such as HPV16E7 and HPV18E7 or mutant proteins immunologically cross-reactive therewith.

30 The recombinant IL-12 used as an HPV vaccine adjuvant can be a mixture of IL-12 and vaccine administered at the same site. Alternatively it can be used as individual components in a combination treatment in which the components are administered individually, e.g. at the same site and time, or at different sites and/or times. For example, IL-12 can be administered topically while a vaccine is given systemically by injection.
35 For example IL-12 administration can be on a daily basis, e.g. for a week from day 0, while injection of vaccine can be on a periodical basis, e.g. at day 0, day 14 and day 28.

DELIVERY OF IL-12 BY MEANS OF cDNA:

IL-12 can be used in the treatment of HPV disease by delivering a polynucleotide such as a cDNA encoding IL-12.

5 This can be given for example in the form of: naked plasmid DNA encoding both chains of IL-12. They can be encoded as separate proteins on the same plasmid either under the control of separate promoters, which can be similar or different, or under the control of a single promoter.

10 Alternatively cDNAs encoding the two chains can be fused together to produce a cDNA coding for a single fusion protein, which can if desired have a peptide spacer located between the sequences corresponding to the two IL-12 subunits.

15 Alternatively the two chains of IL-12 can be encoded on separate plasmids. The two plasmids can be given as a mixture at one or more injection sites, or the plasmids can be injected separately into different injection sites.

Alternatively, a polynucleotide encoding only the p40 subunit of IL-12 can be given: especially where the polynucleotide is to be used to cause expression in cells such as keratinocytes where the other subunit, p35, is constitutively expressed.

20 The polynucleotide such as cDNA encoding either the p40 and p35 subunits or the p40 subunit of IL-12 can be delivered by a vector such as a recombinant viral or bacterial vector. A usable viral vector can be a recombinant vector based on a retrovirus, an adenovirus, an adeno-associated virus a herpesvirus, poxvirus or other virus. The virus can be replication competent, e.g. an attenuated live virus, or it can be a replication-defective virus, e.g. one that is unable to generate infectious new virus particles in the vaccinated subject owing to a genetic defect in the virus, by deletion of an essential viral gene. Alternatively the virus-related vector can be an amplicon associated with a helper virus.

30 Usable bacterial vector systems include *Lactococcus lactis*, attenuated *Salmonella* and other safe bacterial systems.

The IL-12 chains can be encoded as separate proteins in the same virus or bacterium either under the control of separate promoters, which can be similar or different, or under the control of a single promoter. Alternatively, cDNAs encoding the two chains can be fused and made to encode a single fusion protein, as mentioned above. Alternatively the two chains can be encoded in separate vectors.

IL-12 cDNA can also be delivered by liposome delivery.

Administration of naked plasmid DNA can be achieved by injection of an aqueous solution containing the the plasmid DNA. Generally, route of injection of the materials provided hereby can be intramuscular, subcutaneous or intradermal route, e.g. directly into or adjacent to a HPV-associated lesion (tumour, wart).

Alternative usable sites of injection are: skin or mucosa immediately adjacent to an HPV-associated lesion, and skin or mucosal sites further distant from the HPV-associated lesions.

Another recently described delivery method can be applied, by adsorbing the DNA on gold particles and injecting the particles by a gun.

Administration of viral- or bacterial-based vectors can be by injection of a composition, e.g. aqueous composition containing the modified virus or bacterium, by intramuscular, subcutaneous or intradermal route, e.g. directly into a HPV-associated lesion or if not at the site of the lesion then immediately adjacent to the lesion or at a distant site. The vector can alternatively be given at a mucosal surface by intranasal, oral or other administration.

The IL-12 polynucleotide such as cDNA or vector containing such a polynucleotide can be used as a vaccine adjuvant for the treatment of HPV-induced disease.

The associated vaccine can comprise for example a naked plasmid DNA encoding one or more HPV-associated antigens, which can be one or more of the gene products derived from a HPV genome expressed either individually or in the form of a fusion protein. DNA encoding the HPV antigen can be on the same plasmid as the the IL-12 gene or on a separate plasmid.

Alternatively IL-12-encoding polynucleotide can be given in association with HPV-antigen-encoding polynucleotide delivered in a viral or bacterial vector(s) as described above or via liposome delivery. The IL-12 and the HPV antigen(s) can be encoded in the same vector or in separate vectors.

DNA encoding IL-12 chains can code for two separate proteins which associate to form a biologically active molecule or can code for a fusion protein containing sequences of both chains of the IL-12, optionally separated by a spacer aminoacid sequence.

TEST METHODS:

The following test methods were used in the inventors' clinical study mentioned above and further described below, and are also applicable to monitoring during the course of treatments according to the present

invention.

Cytokine mRNA analysis of tumour cells:

5 Tumours analysed here were genital warts from patients with condyloma acuminata. As discussed, these are caused by HPV infection.

Sampling of the genital lesions:

10 The genital lesions utilised in this study were taken at the Department of Genito-Urinary Medicine, Jefferiss Wing, St Mary's Hospital, Paddington, London. In all cases lesions were treated with Betadine (TM) for the 24 hours prior to sampling. Lesions were resected and immediately snap frozen in liquid nitrogen. Samples were then kept at -70 deg.C until analysed.

15 RNA extraction from the biopsies:

20 RNA was extracted from the samples using RNeasy B (from Cambio, Cambridge, UK), a commercial product based on the method of P Chomczynski et al (1987) Anal Biochem 162:156-161. Frozen tissue was put in a tube containing at least 1ml of RNeasy B on ice and homogenised with an electric homogeniser (from OMNI International 1000, Camlab, Cambridge UK). The resultant suspension was transferred to 1.5 ml autoclaved eppendorf tubes and 0.2 ml chloroform was added to each 2 ml of homogenate. Samples were vigorously shaken for 15 seconds and the suspension was left on ice for at least 15 minutes, then tubes were centrifuged at 12,000 g for 15 min at 4 deg.C. The samples divided into two phases, an upper aqueous phase and a lower organic phase. The upper phase was transferred to a new tube and an equal volume of isopropanol was added.

25 To precipitate the RNA, samples were stored at -20 deg.C for at least 16 hours, then centrifuged for 15 minutes at 12,000 g at 4 deg.C. 30 The supernatant was removed and the pellet washed with 70% ethanol. The RNA was briefly dried under vacuum, resuspended in 50-100 micro-l of DEPC-treated water and quantitated by reading at 260 nm on a spectrophotometer. Small aliquots of the RNA were then stored at -70 deg.C.

35 Checking quality of the RNA extracted from the biopsies:

To verify that the RNA extracted from the samples was not degraded, small aliquots were run on an agarose gel containing 6.6% formaldehyde with markers for RNA 18 S and 28 S. The RNA was visualised by staining with ethidium bromide (0.5 micro-g/ml) in ammonium acetate 0.1M for 30-60

minutes. When the bands corresponding to rRNA 18 S and 28 S were visible the gel was photographed and only the samples which showed clear bands for the ribosomal RNA were used for further study.

5 Enzymatic amplification of RNA with RT-PCR:

(a) Synthesis of DNA utilising the RNA as template:

2 micro-g of total RNA extracted from the genital lesions was used as template for reverse transcription. The RNA with 500 ng of poly(T)18
10 primer in a final volume of 20 micro-l was incubated at 65 deg.C for 15 minutes then chilled on ice. The following mixture was prepared for each sample:

10 micro-l of 5X Reverse Transcriptase Buffer
2 micro-l DTT 0.1M (dithiothreitol)
15 5 micro-l 4dNTP mix 8 mM (2mM each)
2 micro-l (20U) RNAsin
10 micro-l water.

The 29 micro-l of this mix were added to the tube containing the RNA. 1 micro-l (200U) of Superscript (TM) Reverse Transcriptase was added
20 to each sample and the tubes were incubated for 1 hour at 42 deg.C. At the end of this incubation 15 micro-l of Tris-Cl 10 mM, EDTA 10 mM, pH 7.5 were added, then 200 micro-l of buffered phenol was added, samples briefly vortexed and centrifuged for 5 minutes at high speed, room temperature. The upper aqueous phase was transferred to a new tube, then 200 micro-l
25 of chloroform:isoamyl alcohol 24:1 were added. After vortexing and spinning at high speed, room temperature, the upper phase was transferred to a new tube, to which 20 micro-l of sodium acetate 3M and 500 micro-l of absolute alcohol were added. Samples were stored at -20 deg.C overnight or at -70 deg.C for 15 minutes, then centrifuged for 15 minutes at high
30 speed, 4 deg.C. The supernatant was removed and the pellet briefly dried under vacuum and resuspended in 100 micro-l of water. The cDNA obtained was stored at -20 deg.C.

(b) Amplification of cDNA with specific primers:

35 5 micro-l of the cDNA obtained by reverse transcription were utilised to amplify specific sequences of cytokines. The primers utilised for PCR amplification were as follows:

IL-1-alpha 5' ATGGCCAAAGTTCGAGACATG

	IL-1-alpha 3'	CTACGCCTGGTTTTCCAGTATCTGAAAGTCAGT
	IL-1-beta 5'	ATGGCAGAAGTACCTAAGCTC
	IL-1-beta 3'	TTAGGAAGACACAAATTGCATGGTGAAGTCAGT
	IL-2 5'	ATGTACAGGATGCAACTCCTG
5	IL-2 3'	TCACGTCAGTGTTGAGATGATGCTTTGACAAAA
	IL-3 5'	ATGAGCCGCCTGCCCCTCCTG
	IL-3 3'	AAGATCGCGAGGCTCAAAGTCGTCTGTTG
	IL-4 5'	ATGGGTCTCACCTCCCAACTG
	IL-4 3'	TCAGCTCGAACACTTTGAATATTTCTCTCTCAT
10	IL-5 5'	ATGAGGATGCTTCTGCATTTG
	IL-5 3'	TCAACTTTCTATTATCCACTCGGTGTTTCATTAC
	IL-6 5'	ATGAACTCCTTCTCCACAAGC
	IL-6 3'	CTACATTTGCCGAAGAGCCCTCAGGCTGGACTG
	IL-8 5'	ATGACTTCCAAGCTGGCCGTG
15	IL-8 3'	TTATGAATTCTCAGCCCTCTTCAAAAACCTTCTC
	IL-10 5'	ATGCCCCAAGCTGAGAACCAAGACCCA
	IL-10 3'	TCTCAAGGGGCTGGGTCAGCTATCCCA
	IL-12 p35 5'	AACTAATGGGAGTTGCCTGG
	IL-12 p35 3'	GGACCTCGCTTTTTAGGAAG
20	IL-12 p40 5'	TCACAAAGGAGGCGAGGTTTC
	IL-12 p40 3'	TGAACGGCATCCACCATGAC
	TNF-alpha 5'	ATGAGCACTGAAAGCATGATC
	TNF-alpha 3'	TCACAGGGCAATGATCCCAAAGTAGACCTGCCC
	TNF-beta 5'	ATGACACCACCTGAACGTCTCTTC
25	TNF-beta 3'	CTACAGAGCGAAGGCTCCAAAGAAGACAGTACT
	IFN-gamma 5'	ATGAAATATACAAGTTATATC
	IFN-gamma 3'	TTACTGGGATGCTCTTCGACCTCGAAACAGCAT
	TGF-beta1 5'	AACATGATCGTGCGCTCTGCAAGTGCAGC
	TGF-beta1 3'	AAGGAATAGTGCAGACAGGCAGGA
30	Actin 5'	GTGGGGCGCCCCAGGCACCA
	Actin 3'	CTCCTTAATGTCACGCACGCTTTC
	CD3delta 5'	ATAGCACGTTTCTCTCTGGC
	CD3delta 3'	ATGTCTGAGAGCAGTGTTCC
	CD4 5'	TGGTGATGAGAGCCACTCAG
35	CD4 3'	CATGTCTTCTGAAACCGGTG
	CD8 5'	TTCCGGGTGTCGCCGCTGGAT
	CD8 3'	GCTGAAGTACATGATGGAGT
	c-fms 5'	TGGTGGCCACAGCTTGGCAT
	c-fms 3'	CTCCTGTGCTAGCACGTTTC

IgG 5' GCATGTACTAGTTTTGTCACAAGATTGGG
IgG 3' TCCACCAAGGGCCCATGC

The following mix was prepared for each sample:

- 5 2.5 micro-l 20X React Buffer
3 micro-l MgCl₂ 25 mM
1 micro-l 4dNTP mix 40mM (10mM each)
2.5 micro-l each primer
31.5 micro-l water

- 10 43 micro-l of the mix were transferred to a 0.5ml eppendorf tube and 5 micro-l of the template cDNA were added. 2 micro-l of thermostable DNA polymerase Tfl (from Cambio, Cambridge UK) was then added. The mixture was then overlaid with 20 micro-l of mineral oil and amplified for 60 cycles at the following temperatures: denaturation: 94 deg.C for 1
15 minute; annealing: 55 deg.C for 1 minute; elongation: 72 deg.C for 2 minutes.

The amplification was preceded by a prolonged period of denaturation at 94 deg.C for 5 minutes and followed by a cycle at 72 deg.C for 10 minutes, to eliminate the remaining activity of the polymerase.

- 20 The presence of the appropriate band was verified by running 20 micro-l of the PCR product on a 1.5% agarose gel containing ethidium bromide. When the gel had been run for an adequate length of time, it was photographed and utilised to transfer the DNA to a nitrocellulose membrane. The gel was denatured for two cycles of 20 minutes each in NaOH
25 0.5M, NaCl 1M, then washed in water and neutralised in Tris-Cl 0.5M, pH 7.4, NaCl 3M for two cycles of 20 minutes. The gel was transferr3ed overnight to a nitrocellulose membrane in SSC 20X utilising Quickdraw blotting paper (from Sigma International). The membrane was then equilibrated with SSC 20X, air dried and baked for 2 hours at 80 deg.C,
30 then stored at 4 deg.C until used.

(c) Confirmation of the identity of the PCR product:

- To confirm the identity of the PCR product the membrane was hybridised with digoxigenin labelled probes that recognise internal
35 sequences of the cytokine amplified by PCR, following the protocol by Boehringer Mannheim in their in-situ hybridisation guide. Internal probes used for hybridization with PCR products were as follows:

IL-1-alpha CATGGGTGCTTATAAGTCATC

	IL-1-beta	CGATCACTGAACTGCACGCTCCGGG
	IL-2	GCACTTGT CACAAACAGTGC
	IL-3	ACACACTTAAAGCAGCCACC
	IL-4	GCGATATCACCTTACAGGAG
5	IL-5	TACATAAAAATCACCAACTGT
	IL-6	GAGGTATACCTAGAGTACCTC
	IL-8	TAAAGACATACTCCAACTT
	IL-10	CAGGTGAAGAATGCCCTTAAATAAGCTCCAA
	IL-12 p35	GAAGAAGTATGCAGAGCTTG
10	IL-12 p40	CCAGCAGGTGAAACGTCC
	TNF-alpha	GGCGTGGAGCTGAGAGATAAC
	TNF-beta	CTACTTCGTCTACTCCCAGGT
	IFN-gamma	AGAGTGTGGAGACCATCAAGGA
	TGF-beta1	AATTTAAGGACACCGTGCCCC
15	beta-actin	CTGAACCCCAAGGCCAACCGCG

Membranes were prehybridised in at least 20ml/100 sq cm of N-lauroyl sarcosine 0.1% v/v, SDS 0.02% v/v and Blocking Reagent for nucleic acid hybridisation (Boehringer Mannheim) 1%, for 1 hour at 37 deg.C. The hybridisation was performed for 4 hours with 10 pmol/ml of oligonucleotide in 4 ml/100 sq cm of hybridisation buffer at 37 deg.C. Membranes were then washed twice at room temperature with SSC 2X, SDS 0.1% v/v, 5 minutes per wash, followed by 2 washes of 15 minutes each at 37 deg.C with SSC 0.1X, SDS 0.1% v/v. Membranes were equilibrated in Buffer 1 (Maleic acid 100mM, NaCl 150mM, pH 7.5) for a few minutes, then incubated in Blocking Reagent 1% for 30 minutes. Membranes were then incubated with anti-DIG antibody conjugated with alkaline phosphatase (Boehringer Mannheim) diluted 1:5000 for 30 minutes at room temperature under gentle shaking. Membranes were washed twice for 5 minutes with Buffer 1 and then transferred briefly to Buffer 3 (Tris-Cl 100mM, pH 9.5, NaCl 100mM, MgCl₂ 50mM). Membranes were then incubated with colour change solution (45 micro-l NBT, 35 micro-l X-phosphate in 10 ml Buffer 3) for 16 hours, when the reaction was blocked by washing in Buffer 1. The visualisation of the correct size band in both the positive control and the sample indicated specificity of the amplified cDNA.

Results:

The results of the RT-PCR analysis in the clinical study are given in the attached tables a to e of the accompanying drawings. The division

into different tables was based on similarity in the pattern of cytokine expression in regressing or non-regressing warts. Table a relates to cases of non-regressing warts with no evidence of IL-2 p40 or IFN-gamma transcription. Table b relates to cases of non-regressing warts with no evidence of IL-12 p40 transcription but with evidence of IFN-gamma transcription. Table c relates to cases of non-regressing warts with evidence of IL-12 p40 transcription. Table d relates to cases of regressing warts.

The intensity of the signals was determined by comparison between samples amplified in the same reaction and then normalised by comparison to the intensity of the actin band.

In the study, the inventors also analysed normal cervical tissue in order to have data on gene expression in normal tissue. Those samples were from uterus which had been removed for reasons not related to HPV infection and were snap frozen as the other samples.

All lesions showed transcripts for IL-1beta, IL-8, IL-12 p35 and TGF-beta1, although at different levels. No wart sample was positive for IL-3, IL-4 or IL-10. IL-4 was seen only once in a normal cervical tissue (NCx2). Two samples were positive for IL-6, whereas transcripts for IL-5 were seen in five samples.

Non-regressing lesions are grouped in Table a and did not show transcripts for IL-2, IL-12 p40 or IFN-gamma. Only three samples showed transcripts for both TNF-gamma and -beta, whereas four samples had transcripts for TNF-beta only, and the remaining four neither. Most samples had transcripts that indicate the presence of T-cells, both CD4 and CD8. Three samples did not show those transcripts, neither for T-cells nor for other immune system cells; some lesions in Table b showed the same pattern. It should be noted that those lesions had bands of low intensity for actin, so the signal for T cells may have been lower than the threshold of sensitivity.

Non-regressing warts grouped in Table b showed transcripts for IFN-gamma, but only two also had transcripts for IL-2. Transcripts for TNF were low for most lesions, though two samples had high levels of both. In general these lesions showed a higher grade of cytokine transcription and therefore a stronger activation of the immune system when compared to the lesions grouped in Table a.

Non-regressing warts grouped in Table c showed transcripts for IL-12 p40, which was never present in either of the previous groups. Three lesions were negative for IL-2 and the former two were also negative

for IL-2 and the former two were also negative for IFN-gamma transcripts, while the remaining lesions had transcripts for both these cytokines. Moreover TNF-alpha was present in every lesion, and was transcribed at rather high levels.

5 The regressing warts grouped in Table d showed a cytokine profile very similar to the one seen for the lesions in Table c: transcripts for IL-12 p40, IFN-beta and IFN-gamma were present in all lesions and IL-2 transcripts were present in 4 out of 5 lesions. Normal cervix showed transcripts for IL-2, TNF and in one case for IFN-gamma, but not for IL-12
10 p40 (see Table e).

 The examination of normal cervical tissue thus showed transcripts for IL-1beta, IL-2, IL-4, IL-8, IL-12 p35, TNF-beta, IFN-gamma and TGF-beta. IL-2 was probably due to the population of resident T cells, which has been shown to be present in normal epithelium. The presence of this
15 population of lymphocytes was confirmed by transcripts for the cellular markers CD3, CD4 and CD8. IL-1beta, IL-4, IL-8, IL-12 p35, TNF-beta, IFN-gamma and TGF-beta could have been produced by keratinocytes or by Langerhans cells or both.

 In the first group of samples there were transcripts for IL-1beta, IL-8, IL-12 p35, TNF and TGF-beta. Although there were T cells in some
20 samples as indicated by CD3, CD4 and CD8 transcripts, no transcripts for IL-2 or IFN-gamma were detected.

 In the second group of samples the pattern of cytokines was similar to that seen in normal cervical tissue with transcripts for IL-1beta, IL-8, IL-12 p35, TNF, IFN-gamma, and TGF-beta. In a few cases there were
25 also transcripts for IL-2. This pattern seemed to suggest a more normal situation.

 The samples in the third and fourth groups had very similar patterns of cytokine expression. In these lesions there were transcripts
30 for IL-1alpha, IL-1beta, IL-2, IL-5, IL-8, IL-12 p35, IL-12 p40, TNF-alpha, TNF-beta, IFN-gamma, and TGF-beta. IL-1alpha and TNF indicate a pro-inflammatory reaction and therefore an immune response. The most remarkable difference between these lesions and those in the previous groups seemed to lie in the presence of transcripts for IL-12 p40, which
35 were never detectable in normal cervical tissue. IL-12 is believed to be necessary for the activation of Th1 lymphocytes and its presence therefore suggests that in these lesions the population of CD4+ T cells is in the process of inducing a DTH type of response (previously reported as correlated to the clearance of the virus: S Aiba et al, 1986, Cancer 58:1246-1251).

The appearance of IL-12 p40 transcripts in a small number of non-regressing lesions was believed to indicate a possibility that the patients from whom these samples were taken were in very early stage of regression but at a time when clinical improvement was not yet measurable.

5 The results suggest a central role of IL-12 in the local immune response to HPV infection, and raise an expectation that IL-12 is causative or adjuvant in relation to wart regression.

IL-12 PROTEIN ANALYSIS:

10 Biopsies of regressing and non-regressing genital warts can be analysed for expression of IL-12 and results compared. The presence of p35, p40 and the heterodimer can be examined using readily adaptable standard immunochemical technique. Antibodies recognising IL-12 are commercially available.

15 IL-12 protein can be detected in material taken from regressing warts, in both keratinocytes and leukocytes. Levels of expression are higher in leukocytes, particularly dendritic cells, than in keratinocytes.

20 The work described herein indicates a role for IL-12 in wart regression and a link between dendritic cell expression of IL-12 and wart regression.

EFFECT OF IL-12 ADMINISTRATION IN AN IN-VIVO MODEL:

25 Mouse keratinocytes expressing HPV 16 E6 or E7 or both can be grafted onto the flanks of syngeneic mice using a transplantation technique which permits reformation of a differentiated epithelium. Intradermal challenge in the ear of these animals with E7 or E6 results in a delayed type hypersensitivity (DTH) reaction. There is a relationship between the induction of DTH and the number of E7 expressing cells used to form the primary graft: there is a threshold inoculum below which although an epithelium forms no DTH is elicited. This immune non-responseiveness under these conditions is maintained on subsequent challenge and the grafted cells are not rejected. Cells are rejected in the absence of induced non-responsiveness, making this a model of HPV infection and the immune response mounted against tumours which are caused by such infection. Reference is made to C McLean et al (1993) J Gen Virol 74:239-245; MA Chambers et al (1994) Eur J Immunol 24:748-45; MA Chambers et al (1994) J Gen Virol 75:165-169; and MA Chambers et al, in 'Proceedings of the 2nd International Workshop on HPV Immunology.

30

35

Cambridge UK' (July 1993) ed. MA Stanley (Plenum Press London 1994) pp267-274).

5 Mice can be primed with low levels of antigen by keratinocyte grafting, e.g. from less than 10^4 to 5×10^5 keratinocytes, then given a second graft with a high inoculum, e.g 10^7 keratinocytes. The graft is not rejected. Animals are then challenged with E7, either as a protein or encoded by and expressed from recombinant vaccinia virus.

10 IL-12 can be supplied to such animals with such an antigen challenge. Various routes of IL-12 supply can be readily tested, including injection of naked nucleic acid encoding it and infection with vaccinia virus able to express it from corresponding nucleic acid carried in the recombinant vaccinia-viral genome. The induction of DTH and the rejection of grafts can be used as a readout of efficiency of the protocols. Supply of IL-12 enhances the immune response mounted against
15 the keratinocyte grafts, as evidenced by a DTH reaction. The effects of different routes of supply of IL-12 can thus be readily tested.

20 The invention is thus susceptible of many modifications and variations, as will be readily apparent to those skilled in the art in the light of the present description; and the present disclosure extends to combinations and subcombinations of the features mentioned shown and described herein and in the drawings and appended claims. Documents cited herein are incorporated by reference in their entire content.

Table a. Results of RT-PCR analysis

Sample	IL-1 α	IL-1 β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12 p35	IL-12 p40	TNF α	TNF β	TGF β 1	IFN γ	Ad	CD3	CD4	CD8	c-fms	IgG	
M49576	-	++	-	-	-	-	-	++	-	++	-	-	++	++	-	++	-	-	-	-	-	
F47463	-	++ ++	-	-	-	-	-	++	-	++ ++	-	-	-	++	-	++	-	-	-	-	-	
M45158	-	++ +	-	-	-	-	-	++	-	++ +	-	-	++	++ +	-	++	-	-	-	-	-	
F44168	-	++	-	-	-	-	-	++	-	++	-	+	++ ⊖	++	-	++	++ +	+	+	++	-	++
F48058	-	+	-	-	-	-	-	++	-	+-	-	-	-	+++	-	++	++	+-	+/	+	+	
M48722	-	++	-	-	-	-	-	+	-	+/	-	-	+	++	-	++	+	+/	+	-	+	
F49088A	-	+	-	-	-	-	-	+	-	++	-	+	+	+	-	++	++	+-	+	+	+	
M48821	-	++	-	-	-	-	-	+	-	+	-	-	+	++	-	++	++	+	++	-	-	
F32299	-	+-	-	-	-	-	-	+-	-	+	-	+	+	+	-	++	++ +	+-	+/	-	+	
M36585	-	+	-	-	-	-	-	+-	-	+	-	-	-	+	-	++	+	+/	+	-	+	

⊖ The intensity is twice the marked

Act = β -actin

Table b. Results of RT-PCR analysis

Sample	IL-1 α	IL-1 β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12 p35	IL-12 p40	TNF α	TNF β	TGF β 1	IFN γ	Act	CD3	CD4	CD8	c-fms	IgG	
M38612	-	++	-	-	-	-	-	++	-	++	-	-	-	+++ +	+++ +	++	-	-	-	-	-	
F47449	-	++	-	-	-	-	-	++ +	-	++	-	++	-	+++ \odot	+++ +	++	-	-	-	-	-	
F49051A	-	++	-	-	-	+	-	++	-	++ ++	-	-	-	+++ \odot	+++ +	++	++ ++	++	++	+	+	
M48920	-	++ +	-	-	-	-	-	++	-	++ ++	-	-	++	+++ +	++	++	++ ++	+	+	+	+	
M50704	-	++	-	-	-	-	-	+/-	-	+/-	-	++	+++ +	+++ +	+	++	++	++	+/-	+	+	
F47716	-	++ +	++ ++	-	-	+	-	++	-	++	-	+++ +	+++ \odot	+++ +	++	++	++ +	++	++	+	+/-	+
F46324	-	+	+-	-	-	-	-	+	-	+	-	+-	-	++	+	++	+-	+-	+/-	+	+	

Act = β -actin \odot The intensity is twice the marked

Table c. Results of RT-PCR analysis

Sample	IL-1 α	IL-1 β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12 p35	IL-12 p40	TNF α	TNF β	TGF β 1	IFN γ	Act	CD3	CD4	CD8	c-fms	IgG
F490888	-	++ +	-	-	-	-	-	++ +	-	++	++	++	++	++ +	-	++	++	++	+	-	++
M45727	-	++	-	-	-	-	-	++	-	++	+	+	+	+-	-	++	++	+	+	-	+
F49789	+	++	-	-	-	-	-	+-	-	+-	+	+	-	+++	+	++	++	+	+/-	+	+
F49663	-	+	++	-	-	-	+	+	-	+	+	+	-	+++	+	++	++	+	+	+	+
F48435	+	++	++	-	-	-	-	+/-	-	+	+	+	++	+++	++	++	++	++	+	-	+
M48134	+	++ +	++	-	-	-	-	++	-	++ +	+	++	++	+++	+	++	++	++	+/-	+	+
F49818	+	++ +	++	-	-	+	+	++ ++	-	+-	++	++	++	+++	+	++	++	++	+/-	-	+
F49413	-	++ ++	++ ++	-	-	++ +	-	++ +	-	++	++	++	++	+++ +	++	++	++	++	++	++	++

⊙ The intensity is twice the marked

Act = β -actin

Table d, Results of RT-PCR analysis

Sample	IL-1 α	IL-1 β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12 p35	IL-12 p40	TNF α	TNF β	TGF β 1	IFN γ	Act	CD3	CD4	CD8	c-fms	IgG	
M49040	-	++	++ +	-	-	-	-	++	-	++	++	-	+++ +	+++	++ ++	++	++	++	+-	+	+	+
F49670	+-	+	+-	-	-	-	-	+	-	+	+	+-	+	+-	+	++	++	++	++	+	+	
F33783	+	++	++ +	-	-	+	-	+	-	++	++	++	++	++	+	++	++	++	++	++	++	
F49213	-	++	+	-	-	-	-	+	-	+-	+	-	+	+	+	++	⊕	+	++	++	++	
F490518	-	+	-	-	-	-	-	+	-	+	+	+-	+	+++	+	++	++	+-	++	+	+	

Table e, RT-pcr analysis of normal cervix

Sample	IL-1 α	IL-1 β	IL-2	IL-3	IL-4	IL-5	IL-6	IL-8	IL-10	IL-12 p35	IL-12 p40	TNF α	TNF β	TGF β 1	IFN γ	Act	CD3	CD4	CD8	c-fms	IgG
NCx1	-	++	++	-	-	+	-	++	-	++	-	+	+++	⊕	++	++	++	++	+/-	-	+
NCx2	-	+	++	-	+	-	-	++	-	+	-	-	+	+	-	++	++	+	+/-	-	+

⊕ The intensity is twice the marked
NCx - normal cervical tissue

Act = β -actin

CLAIMS

1. Use of interleukin-12 (IL-12) or a functional analogue thereof, or of a polynucleotide encoding IL-12 or encoding a functional analogue thereof, as a therapeutic material or as an adjuvant in the treatment of papillomavirus-associated lesions.
5
2. Use according to claim 1, for treatment of warts caused by HPV type 6 and/or type 11, e.g. condyloma acuminata.
10
3. Pharmaceutical treatment material comprising IL-12 or a functional analogue thereof, for use as an immunotherapeutic or as a vaccine adjuvant in the treatment of papillomavirus-associated lesions.
4. Pharmaceutical treatment material comprising in combination (i) IL-12, or a functional analogue thereof, for use as a vaccine adjuvant, and (ii) a papillomavirus antigen, or a vector encoding and able to cause expression of a papillomavirus antigen, for use as a vaccine.
15
5. Pharmaceutical treatment material according to claim 4, wherein component (ii) comprises at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto.
20
6. Pharmaceutical treatment material according to claim 4, wherein component (ii) comprises a polypeptide with at least a substantial part of the sequence of at least one of proteins E6, E7, L1, and/or L2 of HPV type 6, 11, 16 and/or 18.
25
7. Pharmaceutical treatment material according to claim 4, wherein component (ii) comprises a recombinant virus vector encoding and able to cause expression of at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto.
30
8. Pharmaceutical treatment material according to claim 7, wherein the recombinant virus vector comprises at least one recombinant vaccinia virus encoding a polypeptide with at least a substantial part of the sequence of at least one papillomavirus protein selected from E6, E7, L1, and/or L2 of HPV type 6, 11, 16 and/or 18.
35

9. Pharmaceutical treatment material comprising a polynucleotide encoding and able to cause expression of IL-12, or a functional analogue thereof, for use as an immunotherapeutic or as a vaccine adjuvant.
- 5 10. Pharmaceutical treatment material according to claim 9, wherein the polynucleotide forms part of a recombinant virus vector.
11. Pharmaceutical treatment material according to claim 10, wherein the virus vector comprises a genetically disabled herpesvirus vector.
- 10 12. Pharmaceutical treatment material according to claim 11, wherein the virus vector comprises a mutant HSV1 or HSV2 having a deletion in the gH gene, and carrying (at the locus of deletion of gH) an inserted heterologous gene or genes encoding IL-12, or a functional analogue thereof.
- 15 13. Pharmaceutical treatment material comprising in combination (i) a polynucleotide encoding and able to cause expression of IL-12, or a functional analogue thereof, for use as a vaccine adjuvant, and (ii) a papillomavirus antigen, or a vector encoding and able to cause expression of a papillomavirus antigen, for use as a vaccine.
- 20 14. Pharmaceutical treatment material according to claim 13, wherein component (ii) comprises at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto.
- 25 15. Pharmaceutical treatment material according to claim 13, wherein component (ii) comprises a polypeptide with at least a substantial part of the sequence of at least one of proteins E6, E7, L1, and/or L2 of HPV type 6, 11, 16 and/or 18.
- 30 16. Pharmaceutical treatment material according to claim 13, wherein component (ii) comprises a recombinant virus vector encoding and able to cause expression of at least one papillomavirus protein or antigenic fragment or fusion protein corresponding thereto.
- 35 17. Pharmaceutical treatment material according to claim 16, wherein the recombinant virus vector comprises at least one recombinant vaccinia virus encoding a polypeptide with at least a substantial part of the

sequence of at least one papillomavirus protein selected from E6, E7, L1, and/or L2 of HPV type 6,11,16 and/or 18.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/00686

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/20 A61K39/12 A61K39/39 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 00436 (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 7 January 1993 cited in the application see abstract; claims ---	4-6, 13-15
X	EP,A,0 433 827 (F. HOFFMANN-LA ROCHE AG) 26 June 1991 cited in the application see claims 1,30 ---	1,3
A	THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 315, no. 17, 23 October 1986, pages 1059-1064, XP000575611 L.J. ERON ET AL: "Interferon therapy for condylomata acuminata" cited in the application ---	
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *d* document member of the same patent family

Date of the actual completion of the international search

31 July 1996

Date of mailing of the international search report

09. 08. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Le Cornec, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/00686

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF EXPERIMENTAL MEDICINE , vol. 173, April 1991, pages 869-879, XP002009853 S. H. CHAN ET AL: "Induction of Interferon gamma production by Natural Killer Cell Stimulatory Factor: Characterization of the responder cells and synergy with other inducers" ---	
X	SCIENCE, vol. 263, 14 January 1994, LANCASTER, PA US, pages 235-237, XP002009854 L.C.C. AFONSO ET AL: "The adjuvant effect of Interleukin-12 in a vaccine against Leishmania major " see the whole document ---	1,3
X	EUROPEAN JOURNAL OF IMMUNOLOGY , vol. 25, January 1995, pages 137-146, XP000574005 A. MARTINOTTI ET AL: "CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with Interleukin-12 genes" see the whole document ---	1,3
P,A	9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, vol. 0, no. 0, 23 - 29 July 1995, SAN FRANCISCO, CALIFORNIA; USA, page 370 XP000575027 C.G. SCARPINI ET AL: "Cytokine mRNA profiles in genitoanal warts" see abstract -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/00686

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9300436	07-01-93	AU-B- 662910	21-09-95
		AU-B- 1985992	25-01-93
		EP-A- 0592480	20-04-94
		JP-T- 6508988	13-10-94

EP-A-433827	26-06-91	AU-B- 5471294	09-06-94
		AU-B- 6834990	27-06-91
		CA-A- 2032653	23-06-91
		JP-A- 5294999	09-11-93
